key: cord-0954559-ylrr4lxp
authors: K.B., Megha; Nayar, Seema A.; P.V., Mohanan
title: Vaccine and vaccination as a part of human life: In view of COVID‐19
date: 2021-11-21
journal: Biotechnol J
DOI: 10.1002/biot.202100188
sha: 7bac94a2b592df118db2877feff89bb9a1f41858
doc_id: 954559
cord_uid: ylrr4lxp

BACKGROUND: Vaccination created a great breakthrough toward the improvement to the global health. The development of vaccines and their use made a substantial decrease and control in infectious diseases. The abundance and emergence of new vaccines has facilitated targeting populations to alleviate and eliminate contagious pathogens from their innate reservoir. However, along with the infections like malaria and HIV, effective immunization remains obscure and imparts a great challenge to science. PURPOSE AND SCOPE: The novel Corona virus SARS‐CoV‐2 is the reason for the 2019 COVID‐19 pandemic in the human global population, in the first half of 2019. The need for establishing a protected and compelling COVID‐19 immunization is a global prerequisite to end this pandemic. SUMMARY AND CONCLUSION: The different vaccine technologies like inactivation, attenuation, nucleic acid, viral vector, subunit, and viral particle based techniques are employed to develop a safe and highly efficient vaccine. The progress in vaccine development for SARS‐CoV2 is much faster in the history of science. Even though there exist of lot of limitations, continuous efforts has put forward so as to develop highly competent and effective vaccine for many human and animal linked diseases due to its unlimited prospective. This review article focuses on the historical outlook and the development of the vaccine as it is a crucial area of research where the life of the human is saved from various potential diseases.

organism. Active and passive are the two basic mechanisms to acquire immunity. The active immunity provides protection that are produced by the person's own immune system. Usually this type of immunity lasts for many years or for a lifetime. Passive immunity enables effective protection by products produced from humans and transferred to another human usually by injection but wanes within weeks, months, or by years.

Vaccines are usually effective but rarely provide permanent or complete protection from infectious diseases. [2] They generally comprise both the whole/entire disease causing organism and their active constituents that can induce immunogenic response. They are produced by attenuation by growing the disease causing organism under sub-optimal conditions which lessen their disease causing ability. The pathogenic organisms were inactivated using thermal or chemical methods. Some vaccines are developed from components of pathogens such as nucleic acid or from specific proteins or polysaccharides. Another type of vaccine is inactivated toxins from toxin producing microbes. The effectiveness of the polysaccharide vaccine in young children was increased using conjugation of polysaccharides with proteins.

The novel beta-corona virus family member SARS-CoV-2 (severe acute respiratory syndrome coronavirus) is the causative agent for the pandemic COVID-19. The disease mainly spreads through the respiratory droplets from the infected person. As of July 9, 2021-185,291,530 cumulative cases have been reported globally with 4,010,834 deaths as reported by the World Health Organization (WHO). [3] Until now, no particular treatment strategy has been demonstrated to be effective against the COVID-19. The mutation that occurs to the viral genome leads to the antigenic shift and drift, and it keeps spreading from one population to the other. These susceptible mutations ultimately generate unusual variants that let the virus to get away from the immune system even after the vaccine administration. [4] Scientists across the world are joining hands to introduce an innovative approach to remodel drugs, expand vaccines or devices to hinder/obstruct the progression of this devastating pandemic. It is therefore much anticipated that the vaccine should be appropriate for all age groups including pregnant ladies, and lactating mothers out to have quick protection by a single dose, and the protection should last for at least one year ought to give a quick onset of defense with a single dose and should persist the protection for at least one year of administration.

Vaccines, generally inherent in a complex multi-scale system which includes clinical, biological, behavioral, social, environmental, and economical relationships. [5] The action of vaccines is by making our immune system more organized and co-ordinate to identify and remember the foreign pathogenic microbes. Thereby vaccination aids in the generation and storage of antigenic specific memory cells. In future, the frequent susceptibility to the actual disease can make our immune system quickly respond to opsonize the bacteria or F I G U R E 1 Characteristics of a vaccine viruses more effectively. The benefits of vaccination, one of the most economic public health interventions, have not wholly reached target beneficiaries in many low and middle income countries. [6] According to WHO, vaccination imparts an important and successful means to prevent infectious diseases. Due to infectious disease the mortality rate among children can be reduced by the massive immunization plan that mainly hang on with the accessibility of the highly economic and immunologically protective vaccines against most dreadful infectious conditions. [7] There are so many strategies and assured properties associated with the making of a vaccine ( Figure 1 ).

Vaccines are generally unique and are administered to large groups of typically healthy individuals including infants and children too. It is really unsatisfactory that when vaccine itself can induce side effects which creates burden even though the illness itself can exhibit severe fatal side effects. The vaccination should provide a much economical approach thereby reducing childhood disease burden, rather compared with clean water and improved sanitation facility that definitely can reduce transmission of disease but require time consuming and expensive infrastructure investments. [8] Figure 2 ). [9] The urgent need for vaccine development against SARS-CoV2 virus was due to the pandemic announcement of COVID-19 disease by WHO. The succeeding widespread mortalities and morbidities in most countries alarmed researchers and scientists to stood together to eradicate this deadly pandemic. Even tough for normal development of vaccine, it would take more than 10 years but the vaccine against SARS-COV2 goes at really quick pace making a breakthrough in development of vaccine through several reputed research centers and vaccine manufacturing companies to put an end to the fast spreading pandemic. [10] Due to this epidemic situation, the whole process of vaccine development and the clinical trial phase were shortened, so that the vaccine has to get fast tracked within 16-18 month duration without reducing its efficiency and efficacy. There are more than 150 candidate vaccines under development process and further 100 vaccines are in highly advanced stages of development. [12] For developing effective and safe drugs and vaccines against [12] There are many institutions that are committed in developing the COVID-19 vaccine, including many academic/research and vaccine manufacturing companies in India. In association with Oxford University and Astra Zeneca, the Serum Institute of India developed ChAdOx1 nCoV-19 (CoviShield). The first vaccine is devel- Regardless of the availability of the safe and effective vaccine, the impartial distribution to the most vulnerable will be the foremost challenge. The next principal challenge to be fulfilled is by procurement of logistics, their safe dispensing, efficient storage depot, unbroken cold chain (chamber) facility, and their administration at community level. For the perfect accomplishment of COVID-19 vaccine, it should be able to apply for humans in routine, so that it should disrupt the spreading of pandemic from person to person and also defend against both clinical diseases as well as viral transmission.

Vaccines can protect our existence and avoid diseases and disabilities, moreover signify good worth between health mediations. Due to the progression in medical sciences, vaccination protected children from many infectious and contagious diseases. One of the greatest attainments is the eradication of polio. Immunization assists getting protected from dreadful ailments and furthermore prevents spreading of the sickness. In order to introduce immunological memory and thereby defend against the effects of infection, immunization is an approach of stimulating the host's defense in case of a particular pathogen.

Immunization is the principle health intervention used to reduce child mortality. Low paces of immunization not just leave many young children at danger for different serious vaccine-preventable diseases yet additionally serve as an indicator of inadequacies in getting other preventive medical care administrations. [13] Due to the significance of immunization, it is vital that the executions of the program against vaccine preventable illnesses are checked intently. Also, one confronts of this program is defaulting immunization -neglecting to receive the In vaccinated children the long term sequelae related with certain childhood illness such as neurological impairments, hearing loss, and various other physical disabilities can be avoided. In children, constant or recurrent infections in early childhood can lead to poor stunted growth, which in turn adversely affects the adult health, cognitive capacity and finally facing the economic productivity. [14] [15] [16] For example, in children due to measles infection will wipe out the already existing antibodies to different pathogens in months following infection period and made their health state more vulnerable, prone to multiple infections, and possibly leads to death.

In adults, immunization protects themselves from numerous acute con- The safety of the vaccine is considered to be a major public concern and with this regard the requirement for vaccine-induced protection have been related to recent outbreaks of vaccine-preventable diseases such as measles [17] and higher rates of exemptions from schoolentry vaccine requirements. [18, 19] In the H1N1 influenza pandemic reported in 2009-2010, vaccine safety monitoring was the foremost preference. [20, 21] 

Until now, vaccination is regarded as the most expected efficient as well as cost effective interventions for prophylactic precaution against numerous infectious or contagious diseases. [22] During 15 th century, the first evidence of purposeful attempt made to stimulate immunity was accomplished by the Chinese and Turks. Various reports supported and suggested that dried crusts obtained from the small pox pustules were either insert into small scratches in the skin or inhaled into nos- [23, 24] By the end of 1980, the worldwide eradication of smallpox was attained by the introduction of variolation in 17 th century and followed by the concerted vaccination programs made it a complete success. [25] However, despite of the remarkable achievements of Jenner and due to lack of sufficient knowledge about microbiology, it took eight decades to pass for the next step toward the history of vaccine which happened in the Louis Pasteur's experimental laboratory. The term "vaccine" was coined by Louis Pasteur toward the respect of Jenner's significant insight. The concept of attenuation was most specifically formulated by Pasteur and his colleagues confirmed its effectiveness first with the diarrheal disease in chickens caused by Pasteurella multocida, [26] the anthrax an infectious bacterial disease in sheep and most horrible rabies virus in animals and humans. [27] During the last decade of 19 th century, there was a tremendous development in vaccine technology. The key development methods to inactivate whole bacteria for the making of vaccine, the antitoxin production, and the understanding of serum components (antibodies) capable of neutralizing toxins or inhibiting bacterial growth led a great breakthrough in the history of vaccine production. Later, during the last years of 19 th and the initial years of the 20 th century, inactivated whole vaccine for plague, [28] typhoid, [29] and cholera [30] were developed and examined.

The eminent workers responsible for unraveling, and developing the "perception of serum antibodies" were Emil von Behring, Shibasaburo

Kitasato, Alexandre Yersin, Almworth Wright, Emile Roux, and Paul

Ehrlich. During 1923, Alexander Glenny and Barbara Hopkins demonstrated that, due to the action of formalin the diphtheria toxin can be converted into a toxoid. [31] During the initial years of the 20 th century, Calmette and Guerin introduced the more effective technique of serial cultivation of a pathogen by in vitro or in unnatural hosts and they passaged 230 times bovine tuberculosis bacteria in artificial media containing bile to achieve an attenuated strain to defend against human tuberculosis-BCG vaccine. [32] In 1926, a "killed vaccine" was developed for whooping cough using whole Bordetella pertussis and followed in 1927 led to the development of tetanus toxoid and in late 1940′s tetanus toxoid was combined with diphtheria and pertussis (DTP) as children vaccine. In the era of 1950′s put forward the expansion of poliovirus vaccine, in which both an inactivated vaccine and live vaccine were developed. The former by Jonas stalk [33] in 1954 and latter by Alfred Sabin [34] (1961), an oral polio vaccine were easy to deliver and eliminated the spread of polio. In 1960′s, three attenuated vaccine were developed-for measles (1963) by Samuel Katz and John Enders, [35] for mumps (1967) by Maurice

Hilleman, [36] and for rubella virus (1970) by various workers. [37] [38] [39] While [40] serially passaged yellow fever virus in mice and later by Theiler and Smith [41] more successfully attenuated yellow fever virus in chicken embryo tissues.

The early vaccine emerged through genetic engineering was against hepatitis B virus which was licensed in 1986 by an antigen cloned rather grown and hepatitis A was developed in 1990 as a killed vaccine. Three primary vaccines were developed by reassortment: live and inactivated influenza [42, 43] as well as one of the two rotavirus vaccines. [44] The The much advancement in structural biology and reverse vaccinology could be able to describe more effective antigens, while systems biology probably resolve to understand of how modification in the expression level of specific genes connected with protecting immune responses. [46] [47] [48] [49] Therefore, the approach enhances our knowledge of how to induce specific immune responses and, thus, the development of highly specific and potent novel vaccines.

The progress and improvement of vaccines against many diseases causing organism denotes a key innovation in the history of modern medicine. The conventional vaccine strategy has relied on basically two types of microbial compositions of which one to generate vaccine for immunization or rather to produce a protective immune response. During the initial phase, living infectious microbes which are prepared in their weaker stage that are incapable to induce disease was used as were continuously passaged in monkey kidney cells and afterward in chick embryo and measles in chick embryo fibroblast. [50] The live-attenuated vaccines were prepared after attenuating the viral strain thereby making them completely devoid to induce pathogenicity or without virulence but are highly competent to trigger 

The inactivation of the antigen is typically done by using heat or chemicals like formaldehyde or by radiation ( Figure 4 ). After the chemical exposure, the multiplication capability of the pathogen was hindered but has to retain the structural immunogenic intactness as that of its original natural or basic appearance. It is extremely essential to maintain the structural integrity of antigenic epitopes of surface antigens. Therefore, inactivated whole organism vaccine ensures 

The immense progress achieved in biotechnology has made to recognize the peptide site encircling the most important and potential antigenic sites of viral antigens. Therefore, as an alternative of using the whole pathogenic microbe for immunization only the major subunits infections. It has been practiced for many years by utilizing the genetic material to transport the genes for several therapeutic purposes ( Figure 6 ). [52] DNA vaccines are considered as the third generation vaccine that 

Some pathogenic bacteria possess a polysaccharide outer envelope and generally mimics human polysaccharides. So infant's immature immune system and also in younger children could not recognize or respond to the encountered infection. [53] The conjugate vaccines were developed by chemically attaching the polysaccharide to a strong T-cell stimulating antigen such as tetanus and diphtheria toxoids (Figure 7) . Table 2 . [54] The importance of the adjuvant is growing significantly with aging of the population. According to many experts, adjuvants would be an oil-based emulsions, biodegradable particles (liposomes), synthetic and molecular adjuvants. [55] But safety is the primary consideration of the proposed adjuvants. Hence, while preserving the efficacy of an adjuvant it is essential to introduce a method to eliminate the reactive actions of an adjuvant. For the efficient use of adjuvants, they can be combined with particular route of delivery such as transcutaneous or intranasal, oral immunization for stimulating mucosal immunity.

Although diverse in composition and the capacity in stimulating immune system; virosomes, liposomes, and ISCOMS can be assembled around the idea of a lipid vesicle to which both antigenic targets and immunomodulatory molecules can be substituted. [56] The ionic charge can be modified to requirements based on their lipid composition and production system, physical properties, size of the vesicle.

The above mentioned criteria affect the capability of the delivery system to develop depot, which gets attached to antigen-presenting cells (APCs) and the antigen that loads to the delivery system. [56] In several means, these adjuvants enclosed with lipid and associated proteins resemble naturally enveloped bacteria or viruses. The virus-like particles (VLP) take this process a step advanced; where the lipids and antigenic target derives the pathogen directly thus arbitrating a delivery vehicle that is similar to a pathogen lacking the genes required initiating the infections. [57] The accurate and acceptable combination of 

In spite of substantial advancement made by vaccination for many dreadful diseases, the unexpected and highly contagious entry of novel SARS CoV-2 created a serious threat to the community and affected the health services due to unpredictable nature of spreading and disease symptoms. The rapid ongoing Corona Virus Disease-2019 (COVID-19) has significantly increased the demand of introducing most suitable vaccine for this pandemic. Another fact is that due to increased mortality and morbidity, created panic situation among healthcare workers and people throughout the world. [58, 59] This significantly made an urge for the need of vaccine as no proper treatment strategies were effective. The vaccination successfully can create herd immunity thus inhibit or limit the further spreading of virus.

For the successful development of vaccine, the potential antigen selection is one of the important criteria. The corona virus replicate in cytoplasm has positive single strand RNA, constituting mainly with four structural proteins (S protein, E-envelope protein, M-membrane protein, and N-nucleocapsid protein). [60] The S protein mainly triggers the immunological response during disease progression. [61] The types of vaccines developed against SARS-CoV2 are inactivated and live attenuated, nucleic acid based, adenovirus mediated vector, and recombinant subunit vaccines. The inactivated vaccine was prepared by making the non-infectious virus by physical or chemical treatment methods presenting most of the multiple type viral proteins for immune recognition and activation. They can express the stable conformation dependant antigenic epitopes and can be produced in large scale. The inactivated vaccine candidates BBIBP-CorV [62] demonstrated safety and potency in animal studies and PiCoVacc expressed the induction of neutralizing antibodies against SARS CoV2 in rat, mice and Rhesus macaques. The inactivated vaccine developed by Sinovac containing aluminum hydroxide as adjuvant were highly tolerated and developed good immunological response (6 µg/0.5 ml or 3 µg/0.5 ml doses) in healthy individuals during trials. [63] Currently there is attenuated SARS-CoV2 vaccine which utilizes a weakened virus as antigen by genetical modification. One advantage of attenu-ated vaccine is that it can be administered intranasal and can trigger mucosal immune response that can protect the upper respiratory tract. However, the reversion of the virus to its virulent form creates a major concern in this type of vaccine.

The mRNA and DNA vaccine are popular among the nucleic acid vaccine. These vaccines are transcribed to viral proteins after delivery into human cells. Among the four structural proteins, S protein is the most important one that can induce the immunological response.

The mRNA vaccine is the most promising substitute method of vaccine development compared with any other conventional method due to their high potency, high immunological response and economical and rapid production technique. [64, 65] mRNA-1273 was first developed mRNA vaccine developed within 10 weeks after the genetic sequencing of SARS-CoV2. Another four mRNA based vaccine BNT162a1, b1, b2, and c2 constituting separate mRNA coding genes for diverse antigens. [66] CVnCoV, mRNA vaccine developed using non-chemically adapted nucleotides of mRNA. [67] However, the physicochemical properties of mRNA and their distribution toward cellular and organ level, safety, and efficacy in humans remain unidentified. RNA vaccine are usually delivered through lipid nanoparticles (LNPs).On the other hand DNA vaccine enhances the T-cell induction and antibody production, they have low cost production technique and stable long shelf life [68] but their major disadvantage is to cross the nuclear membrane to get transcribed and exhibited very low immunogenicity. The study conducted in rhesus macaques developed both humoral and cellular immune responses towards different DNA vaccine candidate encoding S protein and showed protective level of neutralizing antibodies titers.

The adeno or pox virus are mainly used for the production of vector vaccine in which they act as carrier virus engineered to bear the appropriate gene mainly the S gene for the SARS CoV2. One of the advantages of this technique is that the expression of immunogen upon heterologous viral infection which triggers the innate immunity requisite for adaptive immune response. [69] In contrast, this approach has the possibility to induce earlier immunity towards adenovirus and thereby insufficient to present only negligible amount of SARS CoV2 antigen to the host immune system. The clinical trials of adenovirus type 5 (AdV5) vector carrying recombinant SARS CoV2 works best with the dosage 5 × 10 10 viral particle per ml and produced comparable immune response to 1 × 10 11 . [70] The chimpanzee adeno (ChAd) -vectored vaccine incorporated with full length codon for SARS-CoV2 protein (ChAdOx1 nCoV -19) . Their clinical trials showed a very safe and tolerated immunologic response. Besides exhibited systemic and local reactions including pain, muscle ache and mild febrile response are reported and reaction subsided upon paracetamol administration. [71] The pre-clinical study of Ad26COVS1 containing Ad26 vector encoded with pre-fusion stabilized S protein induced effective neutralizing antibodies. [72] Another approach is the use of inactivated virus vectors in which the viral vectors that present spike proteins on their surface but are inactivated before use. [73] This method can offer the safety of the viral vector not being able to replicate even in immunocompromised hosts after the inactivation process.

The subunit and virus like particle vaccine (VLP) are another category of vaccine. In subunit vaccine, viral proteins are injected to the host to trigger the immune response and exhibited efficacy in protecting animals and humans from viral infections. These vaccines do not exhibit entire antigenic complexity. The major limitation in this type of vaccine is that it may create an unbalanced or uncontrolled immune response. [74] The study conducted by the Yang and co-workers developed subunit vaccine using baculovirus expression system containg 319-545 of CoV2 receptor binding domain (RBD). Virus like particle vaccine comprises the protein based vaccine containing the protein from the capsid. [75] For controlling the spread of viral infection, neutralizing antibodies (NAb) can plays a pivotal role. [76] The generally used antibody forms are functional antigen binding fragments, single chain variable fragments, single domain and monoclonal antibodies (mAb). The NAbs can be isolated from the patients who are recovered from the CoV2 infection. NAbs specifically targets RBD's of SARS CoV2 which can serve as an important treatment approach towards viral infection. [77, 78] While considering the immunogenicity in terms of neutralizing antibodies; inactivated and AdV5 vector vaccines are at the lower end, mRNA, and ChAdO×1 nCoV-19 are on the medium range and the recombinant protein elicit higher titer values of neutralizing antibodies. The tolerability of the inactivated and recombinant protein is comparatively good followed by mRNA which exhibited increased reactogenicity after second dose and then the AdV vectored vaccine. [79] Old individuals often require higher titers than younger individuals. So vaccine with higher titer such as the mRNA and AdV vectored vaccine might improve the titers in this age group. But the vaccination for the children should be handled with great concern as they show much reactogenicity than adults and low dose might be preferable for this group especially for mRNA and AdV vaccine.

In terms of immunogenicity, inactivated and AdV5 based vaccine shows lower rank followed by ChAdO×1-based and mRNA vaccine and finally the best performance was exhibited by adjuvated, protein based vaccines. [79] Many of the vaccine candidates are administrated intramuscularly and provide increased production of IgG level and provide better protection towards the lower respiratory tract than the upper respiratory tract. The vaccine that can be functional through intranasal route especially live attenuated or viral vector vaccine can aid strong mucosal immunity as well as IgG response which create a great advancement towards the vaccine against SARS-CoV2.

For the identification of antigens that are appropriate for disease avoidance, detailed and thorough information of their biology, etiology, and structural arrangement of the pathogen, communication with cellular receptors in host system and its disease inducing mechanism are essential. It is also important to know the route of entry and subsequent replication sites and cycles of the desired pathogen. Because knowing these details are crucial that different vaccination strategies might be implemented to protect against pathogens entering via different routes such as the respiratory (influenza, pneumococcus), gastrointestinal (Salmonella) or genital tracts (Herpes simplex virus [HSV] or HIV), or entering the bloodstream by injury/injection (hepatitis B/C) or mosquito bite (malaria, filariasis, dengue). [80] [81] [82] Generally, less than one tenth of the vaccine candidates achieve licensure due to the high failure rate of the unpredictable nature of the biological organisms required for the vaccine production and the variability of how the human immune system will detect process and react to the vaccine antigen. Appropriate levels of immune response may be produced by some vaccine candidates but they may induce significant adverse reactions. But some may be safe but ineffective at preventing diseases. Although incorporating multiple antigens into one single vaccine, the challenges related with developing safe and effective vaccines are even greater. The continuous research towards the discovery of a new vaccine antigen and novel approaches to immunization usually take years for the fulfillment and cost millions of dollars. After successful discovery, to reach the final licensing point many improvements must be conducted.

In the pre-clinical stage of the development, initial study is based on understanding the pathogen and disease condition mainly focused to resolve most appropriate vaccine characteristics concerning both potential antigens and the type of immunological response that the vaccine must exert to defend against infection by humoral and/or cellmediated immunity. [83] During vaccine development, consistent manufacturing procedure that would ensure a product conformity from lotto-lot all the way through clinical studies are followed and as well as on the market. [84] A number of in vitro and in vivo tests are executed to demonstrate potential immunogenicity of the purified antigen, by using suitable established animal models for this study. Initial toxicity evaluation and dose-response studies were also carried out.

The prime objective of phase I trials determines the safety of the candidate vaccine in dose-setting studies with a small group (i.e., tens to hundreds) of human volunteers. [85] These study are either performed in open-label/blinded trials. The phase I trials are executed in healthy individuals; on the other hand, if the vaccine's target population varies such as infants, older adults, pregnant women are involved, phase I trials may be united with phase II trials as a time and cost-saving measure. [86] In this particular instance, a small group of participants are brought together to complete the phase I section of the trial, pursued by large number of participants in phase II trial.

The major aim of phase II trials is to assess the safety and tolerability of the vaccine in wider study population (hundreds to thousands) that display more immunogenicity by surrogate markers of the candidate vaccine. [85] To predict the vaccine's protective effect, the immunologic markers selected should be suitable to the preferred response. For example, cell mediated immunity represents an imperative role to prevent Varicella zoster reactivation. As a result, activated CD4+ T-cell incidents were assessed to evaluate immunogenicity of the newly developed vaccine candidate. [87, 88] 

Phase III vaccine trials, conducted particularly in large study group containing more than 10,000 volunteers, multicenter, randomized and controlled trials participating at risk for the targeted disease condition. [85] The vaccine efficacy (VE) is the primary outcome obtained from this controlled study is about the, which signifies the risk reduction (RR) in developing a predetermined result in the vaccinated population compared to the unvaccinated population:

The infection incidence (e.g., polymerase chain reaction to confirm varicella zoster virus) or some other neurological complication (e.g., postherpetic neuralgia) may be interpreted by the pre-specified result.

In In United States, FDA approves new vaccine candidates by the same method as similar to that of biological products. Initially, before commencing clinical trials an Investigational New Drug application (NDA) has to be proposed. After successful completion of phase III trials, a Biologic License Application (BLA) is send to FDA for review before commencement of vaccine to the market. [89] The FDA intends to make a decision on at least 90% of new BLAs within 10 months of approval as mandated by the goal set by the Prescription Drug User Fee Act (PDUFA). [88] However, according to estimates, only 50% to 60% of new NDA's were accepted during the financial years 2010 to 2014. BLA will obtain approval upon initial application followed by the submission of the additional details provided as per requisition by the FDA. The time between application and approval may be as long as 2 years. [89, 90] After the vaccine is brought to market and administered, phase IV trials continue to wider population than in clinical trials to collect safety and efficacy results. [89] These studies are essential requisite for the FDA on a case-by-case basis, to describe additional safety and effectiveness in various sub-populations.

The first administration of vaccination were performed through scarification (i.e., disruption of the epidermal layer of skin), but today's vaccination administered by means of hypodermic needle and syringe into muscle (i.m.), subcutaneous tissue (s.c.), or skin (i.d.). [91] It can also be delivered through mucosal route, that is, orally or nasally, but particular formulations are required for the delivery route to avoid antigen degradation or inactivation. Due to the adverse and highly acidic location in which the vaccine must endure inside the gastrointestinal tract, oral administration is highly recommended to ensure adequate absorption and prevent low bioavailability. [92, 93] Based on the different availability of vaccine, different administration route is required based on the formulation of the vaccine, cellular uptake or tissue vascularity. Therefore, each administration route has its own benefits and drawbacks.

While considering the quickness and simplicity for vaccine delivery the most common route is by intra muscular or subcutaneous administration. By this method relatively large doses can be delivered in thigh muscle angled at 90 • "deltoid or anterolateral" where sufficient blood supply is seen. Majority of vaccines to date have been administered intramuscularly. Examples include DT, hepatitis A and B, influenza, HiB, HPV, pneumococcal, and meningococcal. [94] Generally, i.m. or s.c. administrations have been recorded to be painful and less effective in arising broad immunogenicity consequently necessitating higher levels of vaccine immunogen levels compared to the skinbased immunizations. [94] [95] [96] [97] [98] So that multiple applications are generally needed to evoke a strong immunological response.

In comparison to intramuscular administration, subcutaneous injections are administered into adipose tissue (buttocks) at 45 • angle.

because of the limited drainage and vasculature. Although the prolonged existence of antigen may lead to increased immunogenicity due to prolonged absorption, that may leads to an amplified number of incidence of local adverse reactions like granulomas and abcesses predominantly when co administered with adjuvants. Overall few vaccine are administered s.c. than i.m. they are varicella, Q-fever, IPV, and some MMR/MMRV vaccines. [94] Some vaccines such as pneumococcal, MMR, yellow fever and rabies can be administered either by s.c.

or i.m. depending upon the manufacturer's instruction. [94] 10.3 Cutaneous immunization

The first method of immunization was performed by scarification on the skin surface, accompanied by the topical administration of cow pox or vaccinia virus to cross react to provide protection against small pox. Mantoux on early 20 th century was first to described the cutaneous immunization, which involves the introduction of substance with a needle parallel (<30 • ) into the skin resulting in a bleb formation. [99] One of the most possible alternatives to conventional immunization is the intradermal injections as they take advantage of the skin's unique immune system to elicit a strong immunological response. While compared to i.m. immunization, i.d. demonstrated improved immunogenicity 5-10 folds much better against influenza, [95, [100] [101] [102] [103] [104] rabies [105] or HBV vaccines [106, 107] but difficulty to administer due to the thin layer of dermis. Only BCG immunizations are currently performed by i.d.

Skin barrier disruption is considered as physical injury that induce local tissue damage or trauma to which immune system responds by releasing danger signals such as heat shock proteins, dsDNA, monosodium uric acid, and other substances that set off triggers cascade of immunological reactions. [108, 109] Biolistic injections, [110] electroporation, [111] [112] [113] iontophoresis, [114] ultrasound, [115, 116] and tattooing devices [117] [118] [119] [120] are instances in which cutaneous immunization technique were employed.

Mucosal tissue immunization has benefit of accumulating the vaccine in or near vicinity to the primary site of infection, thus enhancing secretion of IgA by eliciting natural or humoral immune response. [106] The most important benefit of mucosal or specifically oral routes is that they are much easier to administer than any other parenteral administration method and are very less likely to transmit blood borne diseases. Though, several challenges connected to mucosal immunization

however have yet to be resolved. For the successful antigenicity, it must withstand the low pH and enzymatic digestion in the gastrointestinal tract as well as need to enter the epithelial barrier. [121] This can be accomplished only by adapting, enhancing, and improving the vaccine formulation.

Vaccines have made significant impact on public health-care system.

Their impact on reducing mortality rate stood second only while considering the importance and provision of safe drinking water. [121] Individuals are given vaccine to protect them from several infections, but Vaccine effectiveness is the potentiality of the vaccine to prevent the outcome of interest in the real world. Vaccine effectiveness can be divided into-direct, indirect, total, and overall effects. The direct effectiveness compares the risk associated in the randomly selected individuals with vaccinated individual. [122] The indirect effect estimates of the dissimilarity in the degree of safety received by unvaccinated individual in the incidence or lack of a vaccination program. The total effectiveness covers the relative infection risk rate in vaccinated individual compared to non-vaccinated individual before the commencement of a vaccination program. [124] As a consequence, the overall effectiveness of vaccination demonstrates the outcome of the vaccination program as well as the influence of individuals who is vaccinated. [125] The disease transmission reduction rate for an average individual in a population with a specified degree of coverage of a vaccination program compared with average individual in an equivalent population without vaccination program is generally referred as vaccination program effectiveness. [124, 125] Therefore the overall effectiveness is taken into account to estimate the influence of immunization programs at the population level and also it depicts the benefits attained by both immunized and non immunized individuals. [126, 127] F I G U R E 9 Herd immunity

The term "safety" is related the nature of the damage or harm occurred to an individual. Second, while connected to vaccines, there is the risk occurring at the time of vaccination, weeks later or even years or decades later. There is a chance that the appearance of a disease state is mere accidental through vaccination rather than caused by vaccination which is an issue that is very hard to resolve to the satisfaction and justification of both injured personal and the vaccinators. With regard to the above concern, each individual's immune mechanism system varies and there is an unexpected chance or unusual situation in which vaccination causes the disease that is intended to avoid, or it can trigger allergic or adverse reactions as a result of defective immune system. When dealing with population or cohorts of millions of individuals it is difficult to assume that all the vaccine recipients will be unharmed as a result of vaccination instead we expect a lesser chance that a certain proportion could be discomforted due to the variation in immune response toward the vaccine. It must be considered in the combination with the "benefits" that accrue after the use of vaccine not just the "risks." One of the greatest problem remains is that, people are more likely to project the disadvantages of the current injury as more believ-able and powerful than the observed benefits of the absence of disease to be expected in future. This would definitely distort the approval of the safety of a vaccine.

The vaccine safety is a key concern for the public, manufacturers, immunization providers, and vaccine recipient. The benefits of vaccination are indisputable. To maintain a public confidence in immunization program is critical for preventing a decline in the vaccination rates that leads to the outbreaks of diseases. The vast majority of vaccine related adverse effects are mild and are temporary. Naturally pain at the injection site and mild fever may occur. The mild or adverse reactions towards the vaccine are mainly due to the individual differences in the immune responses. There are government authorities that regulate the clinical developments of vaccine. Prior to the grant of a government license, a rigorous review of vaccine safety must be carried out. During an immunization program, the nature and incidence of the adverse events following immunization is monitored continuously.

Vaccines have been shown in human clinical trials to cause common side effects such as discomfort and inflammation at the site of injection, fatigue, malaise, and mild fever. Measurement of inflammatory cells at the site of injection, reduce food intake, loss of body weight, and changes in body temperature could be the mostly exhibited side effects in animals. [128] The adverse reactions after immunization are unexpected and undesirable. The each components present in vaccine may aid complications; it must be ensured that vaccine components do not pose a risk to vaccine safety either separately or in combination. Any adverse medical hazard that happens after immunization but not necessarily happen based on the vaccine side effects usually referred as Adverse Event Following Immunization (AEFI). These unexpected actions can be categorized into five based on the cause of the event. These events are associated with the vaccine products and quality defects, due to immunization mistake, because of over anxiety about immunization and some coincidental events. The adverse events due to vaccines occur only with a certain frequency. The frequent and minor reactions after vaccination usually exhibited are fever and malaise. The allergic reactions toward vaccine antigen or its component may cause unusual and serious reactions. Vaccine development has a lot of challenges to face, including the identification of safe and effective adjuvants, antigens and the most acceptable suitable delivery mechanism and it should be significant in balance with cost, risks, and benefits. [129] 

Human vaccines have several kinds of benefits, but their potential for further impact is also significant. Scientific advancements can be implemented to accelerate production and thereby simplify the delivery of vaccines, but the commitment toward the society for the immunization programs that must be maintained to gain the full benefits of this 

Ten great public health achievements-United States

A framework for research on vaccine effectiveness

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infection

A systems approach to vaccine decision making

An assessment of interactions between global health initiatives and country health systems

Cost-effectiveness and economic benefits of vaccines in lowand middle-income countries: A systematic review

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Vaccine against Covid-19 disease -present status of development

Draft Landscape of Covid19 Candidate Vaccines

Prevalence and predictors of immunization among innercity infants: A birth cohort study

Long-term consequences of stunting in early life

Killing me softly: The fetal origins hypothesis

Early-life health and adult circumstance in developing countries

Measles outbreak in a highly vaccinated population

Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases

Individual and community risks of measles and pertussis associated with personal exemptions to immunization

Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)

The development of vaccines: How the past led to the future

An inquiry into the causes and effects of the variolae vaccinae, a disease discovered in some of the western counties of England

By Edward Jenner, MDFRS & C. printed, for the author, by Sampson Low: and sold by Law

Vaccination: A history. From lady Montagu to genetic engineering

Edward Jenner and the history of smallpox and vaccination

De l'attenuation du virus du cholera des poules

Méthode pour prévenir la rage après morsure

Remarks on the plague prophylactic fluid

Experimentelle Untersuchungen zur Frage der Schutzimpfung des Menschen gegen typhus abdominalis

Zur aktiven Immunisierung des Menschen gegen Cholera

Diphtheria toxoid as an immunising agent

La vaccination préventive contre la tuberculose par le" BCG

Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines

Studies on variants of poliomyelitis virus: I. Experimental segregation and properties of avirulent variants of three immunologic types

Studies on an attenuated measlesvirus vaccine: General summary and evaluation of the results of vaccination

Live, attenuated mumps-virus vaccine: Protective efficacy as measured in a field evaluation. The New England

Rubella vaccination: A review of practical experience

Experimental live attenuated rubella virus vaccine: Clinical evaluation of Cendehill strain

Attenuation of RA 27/3 rubella virus in WI-38 human diploid cells. American Journal of Diseases of Children

Vaccination de l'homme contre la fièvre jaune

The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus

Development and characterization of cold-adapted viruses for use as live virus vaccines

The protective effect of vaccination against epidemic influenza B

The new pentavalent rotavirus vaccine composed of bovine (strain WC3)-human rotavirus reassortants

Nobel Prize.org.Nobel Media AB2020.Tue.6oct2020

Vaccine discovery and translation of new vaccine technology

Systems biology of vaccination for seasonal influenza in humans

Vaccines: The fourth century. Clinical and Vaccine Immunology: CVI

Ethics

DNA vaccination/ geneticvaccination (pp. 198)

The past, current and future trends in DNA vaccine immunisations

The impact of protein-conjugate polysaccharide vaccines: An endgame for meningitis?

Recent advances of vaccine adjuvants for infectious diseases

New horizons in adjuvants for vaccine development

Influenza virosomes as vaccine adjuvant and carrier system

Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems

Too much information, too little evidence: Is waste in research fuelling the covid-19 infodemic

Deaths in healthcare workers due to COVID-19: The need for robust data and analysis

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. The Lancet Infectious Diseases

Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2

Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: Report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial

mRNA vaccines -A new era in vaccinology

An evidence based perspective on mRNA-SARS-CoV-2 vaccine development

Pfizer and BioNTech dose first participants in the U.S. As part of global COVID-19 mRNA vaccine development program | pfizer

CureVac's optimized mRNA platform provides positive preclinical results at low dose for coronavirus vaccine candidate-CureVac

DNA vaccines -How far from clinical use?

Emerging viruses and current strategies for vaccine intervention

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Draft Landscape of COVID-19 Candidate Vaccines

Molecular basis of coronavirus virulence and vaccine development

Production of viruslike particles for vaccines

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections

Developing Covid-19 vaccines at pandemic speed

Broad neutralization of SARS-related viruses by human monoclonal antibodies

SARS-CoV-2 vaccines in development

Paths to a malaria vaccine illuminated by parasite genomics

Strategies for designing and monitoring malaria vaccines targeting diverse antigens

The march toward malaria vaccines

The vaccine development process

Non-clinical safety assessment of single and repeated administration of gE/AS01 zoster vaccine in rabbits

WHO technical report annex 1: guidelines on clinical evaluation of vaccines: regulatory expectations. 36e96

The clinical development process for a novel preventive vaccine: An overview

A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults

Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: A phase 1/2a randomized, placebo-controlled study

Vaccines in the pipeline: The path from development to use in the United States

FY 2015 performance report to Congress for the Prescription Drug User Fee Act

Old and new: Recent innovations in vaccine biology and skin T cells

Oral vaccine delivery-new strategies and technologies

Physical enhancement of transdermal drug application: Is delivery technology keeping up with pharmaceutical development?

Department of Health; Australian Government

Antibody responses after dose-sparing intradermal influenza vaccination

Dynamic control of needle-free jet injection

Piezoelectric control of needle-free transdermal drug delivery

Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin

L'intradermo-réaction a la tuberculine et son interprétation clinique

Low-dose intradermal and intramuscular vaccination against hepatitis B

PAMPs and alarmins: all we need to know about danger

Dose sparing with intradermal injection of influenza vaccine

Serum antibody responses after intradermal vaccination against influenza

Quantitative and qualitative analysis of antibody response after. Vaccine

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults

Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles

An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis

Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine: A cost reduction strategy

Lowdose intradermal and intramuscular vaccination against hepatitis B

DAMPs, PAMPs and alarmins: All we need to know about danger

Innate and adaptive immune responses to cell death

Intradermal ballistic delivery of micro-particles into excised human skin for pharmaceutical applications

Topical gene transfer into rat skin using electroporation

Enhancement of the effectiveness of electroporation-augmented cutaneous DNA vaccination by a particulate adjuvant

Induction of cytotoxic T-lymphocytes by electroporationenhanced needle-free skin immunization

Transdermal iontophoresis: Combination strategies to improve transdermal iontophoretic drug delivery

Saving cells from ultrasound-induced apoptosis: Quantification of cell death and uptake following sonication and effects of targeted calcium chelation

Ultrasound and transdermal drug delivery

Drug Delivery by Tattooing to Treat Cutaneous Leishmaniasis Scientific Reports

Polymer multilayer tattooing for enhanced DNA vaccination

DNA vaccines and intradermal vaccination by DNA tattooing. Intradermal Immunization

Vaccination with human papillomavirus type 16-derived peptides using a tattoo device

A short history of vaccination. Vaccines. Saunders

Estimation of the direct and indirect effects of vaccination

Measures of the effects of vaccination in a randomly mixing population

Overview of vaccine field studies: Types of effects and designs

Assessing indirect, total, and overall effects. Design and analysis of vaccine studies

Evaluating the cost-effectiveness of vaccination programmes: A dynamic perspective

Economic evaluation of vaccination programs: The impact of herd-immunity

Pre-clinical toxicology considerations for vaccine development

Recombinant vaccines and development of new vaccine strategies

The authors wish to express their thanks to the Director and Head, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medi- 

The authors declare that they have no conflict of interests.

The authors declared that the research data referred to correctly cited in the manuscript's reference section.

Mohanan P.V. https://orcid.org/0000-0001-9631-2938